These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Hetherington S; Hughes AR; Mosteller M; Shortino D; Baker KL; Spreen W; Lai E; Davies K; Handley A; Dow DJ; Fling ME; Stocum M; Bowman C; Thurmond LM; Roses AD Lancet; 2002 Mar; 359(9312):1121-2. PubMed ID: 11943262 [TBL] [Abstract][Full Text] [Related]
27. Thrombotic thrombocytopenic purpura associated with abacavir in a patient with HIV infection. Olszewski AJ; Shapiro JM J Intensive Care Med; 2003; 18(3):156-9. PubMed ID: 14984635 [TBL] [Abstract][Full Text] [Related]
28. Scientists find some genes a bad omen for anti-HIV drug. Stephenson J JAMA; 2002 Apr; 287(13):1637. PubMed ID: 11926874 [No Abstract] [Full Text] [Related]
29. Large lymphadenopathies complicating the abacavir hypersensitivity reaction. García JT; González PR; Hernández-Mora MG; Novoa SR; Quintana FB; Lahoz JG; Vázquez VS AIDS; 2007 Oct; 21(16):2254-6. PubMed ID: 18090059 [No Abstract] [Full Text] [Related]
30. Abacavir warning. AIDS Patient Care STDS; 2000 Nov; 14(11):617. PubMed ID: 11155904 [No Abstract] [Full Text] [Related]
31. Screening for abacavir hypersensitivity. Deresinski S AIDS Alert; 2007 Dec; 22(12):140-1. PubMed ID: 18411482 [No Abstract] [Full Text] [Related]
32. Drug hypersensitivity in HIV. Phillips E; Mallal S Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):324-30. PubMed ID: 17620824 [TBL] [Abstract][Full Text] [Related]
33. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase. Chui CK; Brumme ZL; Brumme CJ; Yip B; Phillips EJ; Montaner JS; Harrigan PR Clin Infect Dis; 2007 Jun; 44(11):1503-8. PubMed ID: 17479950 [TBL] [Abstract][Full Text] [Related]
34. Longitudinal evaluation of cardiovascular disease-associated biomarkers in relation to abacavir therapy. Hammond E; McKinnon E; Mallal S; Nolan D AIDS; 2008 Nov; 22(18):2540-3. PubMed ID: 19005279 [No Abstract] [Full Text] [Related]
36. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. Martínez E; Larrousse M; Podzamczer D; Pérez I; Gutiérrez F; Loncá M; Barragán P; Deulofeu R; Casamitjana R; Mallolas J; Pich J; Gatell JM; AIDS; 2010 Jan; 24(3):F1-9. PubMed ID: 20009917 [TBL] [Abstract][Full Text] [Related]
37. Abacavir hypersensitivity. Vandekerckhove L; Blot S; Vogelaers D N Engl J Med; 2008 Jun; 358(23):2514-5; author reply 2515-6. PubMed ID: 18525052 [No Abstract] [Full Text] [Related]
38. Abacavir plus lamivudine: a thymidine analogue-sparing NRTI backbone. Moyle GJ AIDS Read; 2003 Nov; 13(11):528, 533-5. PubMed ID: 14649622 [No Abstract] [Full Text] [Related]
39. Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction? Bracciale L; Santangelo R; Fanti I; Prosperi M; Colafigli M; Di Giambenedetto S; Marchetti S; Di Franco A; Cauda R; De Luca A Antivir Ther; 2009; 14(1):99-101. PubMed ID: 19320242 [TBL] [Abstract][Full Text] [Related]